A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health. Through our product, the Proteograph® Product Suite (Proteograph), we provide researchers with unbiased, deep, rapid and large-scale access to the proteome, enabling biological discovery that has historically been impractical. With our pioneering proprietary engineered nanoparticle (NP) technology and the Proteograph Product Suite, we provide the most complete, precise, and scalable platform for deep, unbiased proteomics to power population-scale studies and data-driven biology. Proteins are the functional drivers of biology and the primary targets of most approved drugs. Unlike DNA, which is largely static over an individual’s lifetime, the proteome is dynamic, reflecting real-time biological processes, disease states, and responses to therapeutic intervention.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -74M | -74M | -87M | -86M | -93M | -71M |
| EPS | $-1.28 | $-1.28 | $-1.39 | $-1.35 | $-1.49 | $-1.17 |
| Free Cash Flow | -46M | -46M | -50M | -66M | -71M | -53M |
| ROIC | -29.1% | -28.4% | -26.4% | -21.7% | -20.8% | -14.2% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.14 | 0.12 | 0.10 | 0.09 | 0.07 |
| Dividends/Share | $0.00 | - | - | $0.00 | - | - |
| Operating Income | -78M | -78M | -100M | -103M | -97M | -71M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -28.4% | -25.1% | -26.4% | -20.4% | -19.6% | -15.2% |
| Shares Outstanding | 58M | 58M | 62M | 64M | 62M | 61M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 19M | 29M | 46M | 53M | 51M | 44M | 44M |
| SG&A | 15M | 46M | 59M | 59M | 57M | 43M | 43M |
| EBIT | -34M | -71M | -97M | -103M | -100M | -78M | -78M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -33M | -71M | -93M | -86M | -87M | -74M | -74M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 175K | 473K | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -7.6% | -14.2% | -20.8% | -21.7% | -26.4% | -28.4% | -29.1% |
| ROE | N/A | -15.2% | -19.6% | -20.4% | -26.4% | -25.1% | -28.4% |
| ROA | -7.4% | -14.5% | -18.1% | -18.7% | -23.6% | -22.2% | -24.9% |
| Cash Flow | |||||||
| Op. Cash Flow | -21M | -46M | -61M | -59M | -46M | -44M | -44M |
| Free Cash Flow | -25M | -53M | -71M | -66M | -50M | -46M | -46M |
| Owner Earnings | -31M | -77M | -102M | -106M | -80M | -66M | -66M |
| CapEx | 4.5M | 6.9M | 10M | 7.3M | 3.6M | 1.8M | 1.8M |
| Maint. CapEx | 2.4M | 4.9M | 7.8M | 13M | 6.2M | 6.1M | 6.1M |
| Growth CapEx | 2.2M | 2.0M | 2.4M | 0 | 0 | 0 | 0 |
| D&A | 2.4M | 4.9M | 7.8M | 13M | 6.2M | 6.1M | 6.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 13K | 35K | 20K | 13K | 12M | 10M | 10M |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 8.4% | 9.6% | 9.1% |
| Stock-Based Comp | 7.3M | 26M | 34M | 34M | 28M | 15M | 15M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -47M |
| Cash & Equiv. | 334M | 233M | 53M | 32M | 41M | 47M | 47M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.07 | 0.09 | 0.10 | 0.12 | 0.14 | 0.00 |
| Interest Coverage | N/A | -3248.8 | N/A | N/A | N/A | N/A | N/A |
| Equity | N/A | 503M | 447M | 397M | 328M | 259M | 259M |
| Total Assets | 442M | 539M | 488M | 436M | 367M | 296M | 296M |
| Total Liabilities | N/A | 36M | 41M | 39M | 39M | 37M | 37M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -55M | -127M | -219M | -306M | -392M | -466M | -466M |
| Working Capital | 425M | 398M | 422M | 317M | 238M | 186M | 186M |
| Current Assets | 433M | 412M | 435M | 331M | 253M | 202M | 202M |
| Current Liabilities | 8.1M | 13M | 13M | 13M | 15M | 16M | 16M |
| Per Share Data | |||||||
| EPS | -2.48 | -1.17 | -1.49 | -1.35 | -1.39 | -1.28 | -1.28 |
| Owner EPS | -0.52 | -1.27 | -1.64 | -1.66 | -1.29 | -1.15 | -1.15 |
| Book Value | N/A | 8.27 | 7.16 | 6.21 | 5.26 | 4.51 | 4.51 |
| Cash Flow/Share | -0.35 | -0.76 | -0.97 | -0.92 | -0.74 | -0.77 | -1.17 |
| Dividends/Share | N/A | N/A | N/A | 0.00 | N/A | N/A | 0.00 |
| Shares Out. | 59.3M | 60.8M | 62.4M | 63.9M | 62.3M | 57.5M | 57.5M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -1.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.6 | 0.7 | 0.3 | 0.4 | 0.4 | 0.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -0.7% | -4.0% | -22.6% | -52.7% | -35.3% | -43.7% | -41.5% |
| Market Cap | 3.8B | 1.3B | 314M | 126M | 141M | 106M | 112M |
| Avg. Price | 65.06 | 40.58 | 10.48 | 3.46 | 1.90 | 2.09 | 1.94 |
| Year-End Price | 64.40 | 21.74 | 5.03 | 1.97 | 2.26 | 1.84 | 1.94 |
Seer, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Total shareholder yield (buybacks) is 9.1%.
Seer, Inc. (SEER) has a 5-year average return on invested capital (ROIC) of -22.3%. This is below average and may indicate limited pricing power.
Seer, Inc. (SEER) has a market capitalization of $112M. It is classified as a small-cap stock.
Seer, Inc. (SEER) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 9.14%.
Seer, Inc. (SEER) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
Seer, Inc. (SEER) generated $-46 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Seer, Inc. (SEER) has a debt-to-equity ratio of 0.14. This indicates a conservatively financed balance sheet.
Seer, Inc. (SEER) reported earnings per share (EPS) of $-1.28 in its most recent fiscal year.
Seer, Inc. (SEER) has a return on equity (ROE) of -25.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for Seer, Inc. (SEER), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Seer, Inc. (SEER) has a book value per share of $4.51, based on its most recent annual SEC filing.